October 11, 2016 05:17 AM EDT
R&D
China

GSK at­tempts to re­make it­self in Chi­na with lo­cal ties

Tamra Sami

Glax­o­SmithK­line is ramp­ing up its R&D ef­forts in Chi­na af­ter a cou­ple of tu­mul­tuous years in the coun­try.

GSK’s Chi­na R&D Gen­er­al Man­ag­er Li Min …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

A service from the Financial Times